Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPARK: Tazbentetol in ALS
NCT07325591Phase 3Not yet recruiting
- Sponsor
- Spinogenix
- Start
- Oct 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of tazbentetol in amyotrophic lateral sclerosis (ALS), sponsored by Spinogenix. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
tazbentetol
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT07325591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07325591.